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Abstract
Objectives In order to address the current deiciency of health utility evidence relevant for economic evaluations involving 
treatments for rheumatoid arthritis (RA) in the Chinese setting, this study aims to develop a mapping algorithm linking the 
Health Assessment Questionnaire (HAQ) and EQ-5D-5L in a Chinese population of patients with RA.
Methods An estimation sample was obtained from a cross-sectional study that collected HAQ, the pain Visual Analogue 
Scale, and EQ-5D-5L in RA patients in two tertiary referral hospitals in China. Mapping algorithms were derived in this 
study using two alternative regression methods: the beta regression and a multivariate ordered probit regression. The internal 
validity of the mapping algorithms was assessed in each case by calculating predictive performance using a bootstrapping 
procedure.
Results Of the several algorithms developed using these data, predictive performance was shown to be better when VAS 
pain was included as a predictor and when the multivariate ordered probit regression method was used, rather than the beta 
regression method. The algorithms developed were shown to be comparable, in terms of predictive performance, to existing 
mapping studies despite the small sample size of the estimation data.
Conclusion It is hoped that the availability of these algorithms will facilitate the development of cost-efectiveness studies 
evaluating RA treatments in the Chinese health care setting.
Keywords Mapping · Rheumatoid arthritis · Cost efectiveness · Health utilities
Introduction
Rheumatoid arthritis (RA) is a chronic, systemic inlamma-
tory disorder and is primarily associated with progressive 
joint destruction and accompanied by pain, stifness, and 
fatigue. If left untreated over the course of 10–20 years, RA 
may lead to signiicant disabilities and a severe reduction 
in the patient’s quality of life. The overall prevalence of 
RA is relatively constant across nations at 0.5–1% [1]. In 
China, RA is among the top 10 chronic diseases in terms 
of prevalence [2] and the second most common cause of 
disability [3]. Despite this heavy disease burden, the health 
care system in China does not currently cover biologic dis-
ease-modifying anti-rheumatic drugs (bDMARDs), which 
are an innovative class of therapeutic treatments for RA. 
This could potentially change however, as the reimburse-
ment system in China looks set to move towards a value-
based approach to health care coverage. In October 2010, 
the Ministry of Health (MoH) in China signed a memoran-
dum of understanding with the National Institute for Health 
and Care Excellence (NICE) with a view to developing a 
new institution to promote quality and eiciency in health 
care. Furthermore, in an efort to facilitate future economic 
evaluations, Guidelines for Pharmacoeconomic Evaluations 
in China were published in 2011 [4]. These guidelines indi-
cated a preference for the development of cost-efectiveness 
analyses (CEA) with quality-adjusted life years (QALY) 
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using health utility data derived from preference-based, 
generic health-related quality of life (HRQL) instruments.
Although there have been two studies to date conduct-
ing CEA for RA treatments in China [5, 6], neither of these 
studies used health utility evidence that was relevant to the 
Chinese setting. It is not uncommon to ind that clinical tri-
als collect disease-speciic (non-preference based) HRQL 
instruments, as opposed to generic preference-based instru-
ments, capable of deriving health utility values directly. For 
other countries, such as the UK and Spain, studies are avail-
able which map between disease-speciic instruments, e.g. 
the Health Assessment Questionnaire (HAQ) for RA [7], 
and generic preference-based measures of HRQoL, such as 
the EQ-5D [8], via statistical modelling [9–19]. Although 
this approach has its shortcomings, in the absence of directly 
relevant health utility data, it is often considered acceptable 
by the national reimbursement jurisdictions, for example 
NICE [20]. One of the existing CEA studies on RA treat-
ments in China used a mapping algorithm but the values cor-
respond to a tarif from another country [5]. Ideally, health 
utility values employed in CEA studies should relect the 
preferences of the jurisdiction under investigation given that 
there are important diferences between tarifs from diferent 
countries due to cultural diferences [21], and this can have 
a substantial impact on the indings of a CEA study [22]. 
To the authors’ knowledge, there has yet to be any research 
conducted in a Chinese patient population to develop a 
mapping between HAQ and EQ-5D. In order to address 
the current deiciency of health utility evidence relevant for 
economic evaluation in the Chinese setting, the purpose of 
this study was to develop mapping algorithms linking the 
HAQ and EQ-5D-5L in a Chinese patient population. The 
authors anticipate that the availability of these algorithms 
will enable researchers to make use of the growing number 
of studies that have collected HAQ data in RA patients in 
China for the purposes of economic evaluation [23–26].
Methods
Data collection
A cross-sectional study was conducted in two tertiary refer-
ral hospitals, one in the Taizhou 5th Renmin Hospital in 
Jiangsu province and the other in Jianping County Hospi-
tal in Liaoning Province. The collection of data in separate 
regions of China was motivated by eforts to account for the 
signiicant heterogeneity, both in terms of economic devel-
opment and living conditions, that exists across the Chinese 
population [27]. The study was approved by the Institutional 
Review Board and patients with RA were recruited, with 
informed consent, as a consecutive sample (i.e. data collec-
tion in all eligible patients until the desired sample size has 
been achieved) between May and December 2013. Patients 
were eligible if they satisied the following inclusion criteria:
a. they have been previously documented as experiencing 
RA;
b. they were not afected by any other type of musculoskel-
etal problem;
c. they were aged 18 years or older, and identiied as being 
capable of completing self-reported HRQoL question-
naires in Chinese;
d. they had no serious psychiatric disorder or cognitive 
dysfunction; and
e. they were not a current substance abuser.
Eligible subjects were asked to complete HAQ and 
EQ-5D questionnaires by a trained interviewer, in addition to 
a series of questions pertaining to their socio-demographic 
characteristics. Symptom severity and functional limitations 
were measured in subjects by physicians using the ACR clas-
siication of Global Functional Status. The interview proce-
dure—including the interviewer asking the questions—was 
identical in the two recruiting centres.
Instruments
HAQ
The Health Assessment Questionnaire (HAQ), developed by 
Fries and colleagues in 1978 [28], has been widely adminis-
tered and validated in patients for a range of rheumatic dis-
eases. Moreover, it has become a de facto mandated outcome 
measure for clinical trials in rheumatoid arthritis as a com-
ponent of the American College of Rheumatology criteria 
[29], which has subsequently been adopted for use in many 
RA studies in China [23–26, 30]. There were two compo-
nents to the HAQ in this study: the HAQ Disability Index 
(HAQ-DI) and the HAQ pain visual analogue scale (VAS). 
The HAQ-DI consists of 20 items covering 8 domains 
assessing physical disabilities: dressing and grooming, aris-
ing, eating, walking, hygiene, reach, grip, and common daily 
activities. An additional 13 questions were included to assess 
the use of assistive devices in patients and a further 8 ques-
tions to assess whether or not patients received help from 
another person. Responses to each of the HAQ-DI questions 
are graded as follows: without any diiculty (0); with some 
diiculty (1); with much diiculty (2); and unable to do (3). 
The highest score for any component question in a category 
determines the category score. Two composite scores can 
be calculated, one with and one without the aids/devices 
element [27]. The HAQ pain VAS score is measured on a 
horizontal line where each end represents opposite ends of 
a continuum that is standardized to 15 centimeters in length. 
It is labelled with “no pain” and a score of 0 at one end, 
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and “very severe pain” and a score of 100 at the other end. 
Patients are instructed to place a vertical mark on the line 
to indicate the severity of their pain. A score from 0 to 100 
is obtained based on the location of the respondent’s mark.
EQ-5D-5L
EQ-5D-5L is a generic, preference-based HRQoL instru-
ment with ive dimensions including morbidity, self-care, 
usual activities, pain/discomfort, and anxiety/depression 
[31]. Each dimension has ive response levels (no problems, 
slight problems, moderate problems, severe problems, and 
unable to/extreme problems) expressed by a 1-digit number, 
which results in a 5-digit number describing the respondent’s 
health state. Health utility index values were derived using a 
tarif taken from a recently developed study capturing health 
preferences in a sample of individuals from the general pop-
ulation in China [32]. The EQ-5D-5L was selected for use 
rather than the original EQ-5D instrument (EQ-5D-3L) on 
the grounds that the EQ-5D-5L was developed in an efort 
to improve on the original instrument’s perceived lack of 
sensitivity and also to reduce ceiling efects [31, 33].
Statistical methods
A variety of statistical methods have been proposed in the 
published literature for the development of mapping algo-
rithms [34]. Much of the debate in this area has revolved 
around the development of statistical methods capable of 
handling the unique distributional features of health utility 
values [35]. Ordinary least squares (OLS) regression meth-
ods are, at least in theory, inappropriate on the grounds that 
they do not guarantee predicted values will lie within a plau-
sible range [36–38]. One proposed method for circumvent-
ing this problem is to employ regression estimators based 
on features of the beta distribution, which assumes that the 
dependent variable is restricted to a range of values between 
0 and 1 [39, 40]. Another method known as the adjusted-
limited dependent variable mixture model (ALDVMM) was 
developed to capture speciic features of the UK version of 
the EQ-5D-3L tarif [38].
An alternative approach to mapping is to analyse the 
health state descriptions directly, rather than the health util-
ity values, with modelling techniques including multinomial 
logit [41], ordered logistic [42], and ordered probit [43]. 
Unfortunately, these techniques fail to account for the cor-
relations occurring between the diferent dimensions, which 
can give rise to misleading predictions. More recently, a 
study by Conigliani and colleagues showed that this issue is 
avoided by using a multivariate ordered probit method [44].
Mapping algorithms are derived in this study using two 
of the aforementioned regression methods: the beta regres-
sion method and a multivariate ordered probit regression. 
The ALDVMM approach is not employed in this study on 
the grounds that this method was developed for the pur-
poses of analysing health utilities obtained using the UK 
version of the EQ-5D-3L tarif. Although there are addi-
tional analytical methods beyond those discussed in this 
paper, the methods selected have been identiied in ongoing 
research as holding the most potential for the purposes of 
mapping [45]. All analyses were undertaken in R, in which 
the beta regression method was implemented the ‘betareg’ 
package [46] and the multivariate approach was imple-
mented using the ‘mvord’ package [47]. The index values 
of the EQ-5D-5L, which ranged between − 0.391 and 1, had 
to be rescaled given that the beta regression handles values 
lying between 0 and 1. The following equation was used to 
rescale values:
Moreover, values lying at the either end of the distribu-
tion needed to be adjusted given that the beta regression can-
not accommodate values of 0 or 1. As such, 1e-12 was added 
to values equal to 0 and subtracted from values equal to 1.
Choice of predictors
There are multiple ways in which the HAQ could be incor-
porated into a mapping algorithm. The simplest approach 
would be to regress the overall HAQ score onto the EQ-5D. 
Alternatively, one could either use the HAQ item responses 
(i.e. questionnaire responses) or the subdomain scores (e.g. 
dressing, arising). Although the latter methods ofer greater 
detail in the description of HRQoL efects, they may not be 
convenient for practical purposes. For instance, suppose that 
one wanted to predict health utility values using aggregated 
HAQ scores from a published study; mapping algorithms 
derived using item responses or subdomain scores would be 
incompatible with this evidence. Furthermore, the authors 
also felt that the overall HAQ score would be a more appro-
priate predictor given the small sample size of the estimation 
dataset (i.e. fewer parameters requiring estimation). Sup-
plementary analyses are conducted with VAS pain score as 
an additional predictor following recommendations from 
Madan and colleagues [48].
Validation of mapping algorithms
The internal validity of the mapping algorithms is explored 
using bootstrapping procedures. First, a bootstrap sample 
is drawn from the original estimation dataset, with replace-
ment and a sample size equal to that of the original dataset. 
Mapping algorithms are then derived from the bootstrap 
sample, for each of the proposed modelling approaches. 
The estimated algorithms are then used to predict health 
utility values in the original estimation dataset. Finally, the 
rescaled value = (original value + 0.391)∕1.391.
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resulting predictions are compared to the observed health 
utility values using the root mean squared error (RMSE) 
statistic term. This process is repeated until 500 bootstrap 
iterations have been run.
When making predictions using the MV Probit approach, 
probabilities are required for each of the relevant health state 
descriptions. In theory, this would require predictions for 
each of the 3125 feasible states (5^5) that can be constructed 
using the health state description of the EQ-5D-5L given that 
the MV Probit model accounts for correlations between each 
of the ive dimensions. Thankfully, this is not necessary given 
that full health is the only state where between-dimension 
correlations have an impact on the index values derived using 
the Chinese EQ-5D-5L tarif. Consequently, the remaining 
probabilities relect responses to speciic dimensions, inde-
pendent of the other dimensions. Once the probabilities 
have been predicted, EQ-5D values can then be scored. The 
authors decided to use the ‘expected utility’ method proposed 
in a study by Le and Doctor given that this ensures an exact 
calculation via an algebraic equation [49]. The following 
equation was used to conduct these calculations:
where Prob
FullHealth
 represents the probability of a full health 
response and Probi,j represents the probability of a response 
of j on dimension i.
EQ5D prediction =
(
ProbFull Health
)
× 1 + (1 − ProbFull Health)
× (1 − dis) dis = {(ProbAD,2 × 0.258)
+ (ProbMB,2 × 0.345) + (ProbPD,2 × 0.302)
+ (ProbSC,2 × 0.253) + (ProbUA,2 × 0.233)}
× 0.191 + {(ProbAD,3 × 0.258) + (ProbMB,3
× 0.345) + (ProbPD,3 × 0.302) + (ProbSC,3
× 0.253) + (ProbUA,3 × 0.233)} × 0.458
+ {(ProbAD,4 × 0.258) + (ProbMB,4 × 0.345)
+ (ProbPD,4 × 0.302) + (ProbSC,4 × 0.253)
+ (ProbUA,4 × 0.233)} × 0.832
+ {(ProbAD,5 × 0.258) + (ProbMB,5 × 0.345)
+ (ProbPD,5 × 0.302) + (ProbSC,4 × 0.253)
+ (ProbUA,4 × 0.233)}
,
Results
Descriptive statistics and missing data
Table 1 provides descriptive statistics for the estimation 
sample used to derive mapping algorithms. The EQ-5D-5L 
responses in the complete case sample, without VAS pain 
scores (n = 130), covered 43 of the 3,125 health states. The 
same inding was observed in the complete case sample with 
VAS pain scores (n = 125). The proportion of patients report-
ing no health problems on any of the dimensions of the EQ-
5D-5L was below 2% in the sample without VAS pain scores 
(2/130) and less than 1% in the sample with VAS pain scores 
(1/125).
Overall, the degree of missing data in the predictor vari-
ables was small, thus reducing the concerns one might have 
about obtaining less precise parameter estimates in a complete 
case analysis (i.e. due to reduced statistical power). In order 
to examine the validity of assuming that the data are missing 
completely at random (MCAR), logistic regressions were per-
formed to explore any associations between the probability of 
a given predictor being missing and the values observed in the 
other predictors. No statistically signiicant associations were 
observed. This approach follows recommendations relating to 
the methods for best practice in the development of prediction 
models [50]. Additional tests found no statistically signiicant 
associations between the probability of a given predictor being 
missing and the values observed in other auxiliary variables 
(health care setting and region). In view of these indings, the 
authors decided that the risks posed by the missing data in 
the estimation sample were minimal and that a complete case 
analysis would be reasonable.
Model estimates
Parameter estimates, alongside associated standard errors, for 
each of the mapping algorithms can be found in the supple-
mentary materials. R scripts can also be found in the supple-
mentary materials to implement the algorithms in mapping 
applications. This includes Cholesky decomposition matrices 
corresponding to each of the models. Models 1a and 2a refer 
to algorithms developed with HAQ score as the only covariate, 
Table 1  Descriptive statistics 
for the estimation sample
Original data (n = 133) Complete sample, without 
VAS pain (n = 130)
Complete sample, 
with VAS pain 
(n = 125)
Mean (SD) Missing data (%) Mean (SD) Mean (SD)
EQ-5D 0.66 (0.38) 1/133 (> 1%) 0.67 (0.38) 0.67 (0.37)
HAQ 1.22 (0.86) 2/133 (> 2%) 1.20 (0.86) 1.23 (0.84)
VAS pain 50.3 (24.6) 5/133 (> 4%) – 50.0 (24.8)
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while models 1b and 2b refer to the algorithms developed with 
both HAQ score and pain covariates. Note that predictions 
derived using the beta regression models need to be converted 
back onto the original scale between − 0.391 and 1 using the 
following equation:
Validation of mapping algorithms
Table 2 contains the results from the bootstrapping proce-
dures used to test the internal validity of the mapping algo-
rithms. The MV Probit approach exhibited a lower RMSE in 
the majority of the bootstrap samples when compared to the 
beta regression approach. We can, therefore, conclude that 
the MV Probit modelling approach has a stronger predictive 
performance for the estimation sample under investigation 
when compared to the beta regression approach. The results 
also demonstrate that predictive performance is improved 
when the VAS pain covariate is included. Table 2 also shows 
that predictive performance is better in HAQ score less than 
1 compared to those above. This inding is consistent with 
the broader mapping literature [35], i.e. that predictive per-
formance is worse in poorer health states.
Applying the preferred mapping algorithm using R 
code
The results of the bootstrapping exercise showed that the 
optimal mapping algorithm is model 1b, i.e. MV Probit 
method with both HAQ score and pain covariates, due to it 
having the best predictive performance of the four alterna-
tives. There are several stages involved in the prediction of 
EQ-5D values using this algorithm and these have been set 
original scale = (predictions × 1.391) − 0.391.
out in an R script, along with a corresponding example, in 
the supplementary materials (see ‘Supplementary-Materi-
als-2.docx’). This code has been annotated to demonstrate 
how the algorithm can be implemented in the R software 
package and how it can be adapted for the purposes of map-
ping applications involving data containing HAQ and VAS 
pain measures.
In the irst stage of the code, the user is asked to specify 
whether the predicted values will be used to obtain deter-
ministic or probabilistic cost-efectiveness results. In the 
case of the former, point estimates associated with each of 
the mapping parameters (i.e. regression coeicients, thresh-
old values, and the error structure) will be used in the subse-
quent stages. Alternatively, if inputs for a probabilistic cost-
efectiveness analysis are required, predictions will be made 
using parameter estimates that are randomly selected from a 
distribution that relects the sample uncertainty surrounding 
the point estimates of each of the mapping parameters. In 
addition, the user is asked to load HAQ and VAS pain data 
to predict EQ-5D values (example data have been provided 
for the purposes of demonstration).
Stages 2 and 3 of the R script load the parameter esti-
mates associated with model 1b, along with the correspond-
ing variance–covariance matrix, which is used to construct 
sample distributions for each of the parameters. In stage 4, 
probabilities associated with diferent responses to items of 
the EQ-5D-5L are predicted. The code in stage 4 is based 
on the get.prob() function from the mvord package and has 
been adapted to accommodate external data. The inal stage 
of the R script calculates the expected EQ-5D values by 
combining the probabilities derived in the previous step with 
the weights from the tarif estimated by Luo, Liu, and col-
leagues [32].
Table 2  Internal validation of 
mapping algorithms
All patients Patients with HAQ 
less than 1
Patients with HAQ 
between 1 and 2
Patients with 
HAQ greater 
than 2
Models with HAQ covariate only
 RMSE (SD)
  MV probit 0.196 (0.013) 0.065 (0.003) 0.300 (0.019) 0.293 (0.039)
  Beta 0.246 (0.021) 0.094 (0.018) 0.376 (0.037) 0.343 (0.011)
Samples where RMSE 
was lower in the MV 
probit (%)
100 99.6 99.8 91.8
Models with HAQ and VAS pain covariates
 RMSE (SD)
  MV probit 0.177 (0.022) 0.088 (0.022) 0.226 (0.027) 0.277 (0.031)
  Beta 0.196 (0.016) 0.099 (0.014) 0.261 (0.028) 0.281 (0.014)
Samples where RMSE 
was lower in the MV 
probit (%)
94.2 90.8 95.2 63.8
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Discussion
This study is the irst to develop mapping algorithms linking 
HAQ scores to a preference-based measure of HRQoL in a 
Chinese patient population. Until now, the absence of such 
evidence has been a major obstacle for researchers seeking 
to ind relevant evidence to populate CEAs comparing RA 
treatments in China. The availability of the algorithms in 
this study is timely given that there has been an increasing 
number of CEAs conducted in the Chinese health care set-
ting [51]. Moreover, recent actions by the Ministry of Health 
in China point towards an increased use of HTA for policy-
making purposes [52, 53]. It is hoped that the availability 
of R scripts for the implementation of the algorithms will 
facilitate their usage in applied CEA studies.
The mapping algorithms were derived using a cross-
sectional dataset conducted in two hospitals in China that 
collected EQ-5D-5L, HAQ scores, and VAS pain scores 
in patients with RA. Two established statistical method-
ologies—the beta regression and the MV ordered probit 
regression—were employed to develop mapping algorithms. 
These fundamentally diferent approaches to mapping were 
selected in light of ongoing research identifying them as 
holding the most potential for overcoming the well-estab-
lished shortcomings associated with standard OLS regres-
sion methods for the purposes of mapping.
The predictive performance of the mapping algorithms 
developed in this study was tested by estimating the RMSE 
for each model speciication using a bootstrapping proce-
dure. Using this approach, the MV ordered probit model 
exhibited lower prediction errors when compared to the beta 
regression model. Prediction errors were also lower in those 
models including a VAS pain covariate. Overall, the predic-
tive performance of the MV ordered probit models was con-
sistent with the range of RMSEs (0.1644–0.207) observed in 
mapping studies for RA in the published literature [11, 16, 
18, 19, 38, 43]. To the authors’ knowledge, this study is the 
irst to compare the predictive performance of the beta and 
MV ordered probit methods for the purposes of mapping 
in cost-efectiveness applications. In this study, the com-
putational burden incurred when predicting EQ-5D values 
using the MV ordered probit method was not as extensive 
as it could potentially have been. This was because, aside 
from the full health state, between-dimension correlations 
did not have an impact on the resulting values obtained when 
applying the Chinese EQ-5D-5L tarif. It is important to 
acknowledge that a diferent approach may have been needed 
for a tarif with a diferent model speciication.
It is important to recognize that there are several limita-
tions associated with the evidence used in this study. The 
sample size of the dataset used to derive the mapping algo-
rithms was small, with only 130 patients (125 in models 
including the VAS pain as a predictor), in comparison to 
similar studies in the published literature [9–19]. A larger 
sample would be preferable given that an increase in statis-
tical power leads to improved precision in the estimation 
of parameters. Ultimately, this is important in the context 
of a decision model as it can potentially result in reduced 
parameter uncertainty in the cost-efectiveness estimates. 
Although the bootstrapping exercise in this study provides 
an assessment of the internal validity of the mapping pro-
cedures considered in this study, it does not tell us anything 
about the generalizability (or external validity) of the algo-
rithms. Ideally, researchers should investigate the general-
izability of prediction models using an independent dataset 
[50]. Unfortunately, the lack of external data meant that the 
authors were unable to do this.
Another potential limitation in this study is the exclu-
sion of patients with other muscoskeletal problems, which 
may confound the relationship between HAQ scores and 
EQ-5D values. The degree to which this may ultimately 
afect cost-efectiveness results for a given research ques-
tion will depend on the prevalence of other muscoskeletal 
comorbidities in the patient population under investigation. 
Researchers should yield caution when applying the map-
ping algorithms from this paper if the prevalence of such 
comorbidities is high.
There are various ways in which the HAQ data could 
have been speciied in terms of predictors included in the 
mapping algorithms. Some previous studies have captured 
HAQ data in the form of categorical responses to the ques-
tionnaire items using dummy variables [11, 13, 16]. Back-
wards or forwards stepwise selection procedures are typi-
cally used to identify signiicant items rather than using all 
42 individual items. Another approach has been to speciic 
predictors relecting the 8 domains within the HAQ meas-
ure [11], i.e. dressing/grooming, rising, eating, walking, 
hygiene, reach, grip, activities. One advantage of specifying 
HAQ data in terms of item-level responses or domain-level 
scores, rather than overall index scores, is that they have the 
potential to account for a higher proportion of the variance 
in the dependent variable. However, mapping algorithms 
containing item-level responses as predictors can only be 
used to predict EQ-5D values in conjunction with HAQ data 
at the individual patient level; consequently, this rules out 
the possibility of using evidence from the published litera-
ture. Moreover, the speciication of HAQ data in terms of 
item-level responses or domain-level scores implies a larger 
number of predictors and, consequently, a reduction in the 
statistical power for a given sample size. The overall HAQ 
score was considered to be the most appropriate predictor 
for the purposes of this study given the small sample size 
of the estimation dataset (i.e. fewer parameters requiring 
estimation).
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Conclusions
In recent years, the availability of mapping algorithms link-
ing HAQ to generic measures of HRQL has facilitated the 
development of cost-efectiveness studies evaluating treat-
ments for RA [20]. This study is the irst, to the authors’ 
knowledge, to have developed a mapping algorithm between 
HAQ and EQ-5D in a Chinese patient population. The esti-
mation sample was obtained form a cross-sectional study 
that collected data in RA patients in two tertiary referral 
hospitals in China. Of the several algorithms developed 
using these data, predictive performance was shown to 
be better when VAS pain was included as a predictor and 
when the multivariate ordered probit regression method was 
used, rather than the beta regression method. The algorithms 
developed were shown to be comparable, in terms of predic-
tive performance, to existing mapping studies despite the 
small sample size of the estimation data. It is hoped that the 
availability of these algorithms will facilitate the develop-
ment of cost-efectiveness studies evaluating RA treatments 
in the Chinese health care setting.
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